13.91

0.58% 0.08

Immix Biopharma Inc (IMMX)

Overview News Price History Financials Discussions Forecast

Immix Biopharma Inc stock is traded at $13.91, with a volume of 1.05M. It is up +0.58% in the last 24 hours and up +49.09% over the past month. Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Previous Close:

$13.83

Open:

$13.68

24h Volume:

1.05M

Relative Volume:

0.56

Market Cap:

$990.25M

Revenue:

Net Income/Loss:

$-34.98M

P/E Ratio:

-15.12

EPS:

-0.9199

Net Cash Flow:

$-32.77M

1W Performance:

-0.22%

1M Performance:

+49.09%

6M Performance:

+62.50%

1Y Performance:

+535.16%

1-Day Range:

$13.60

$14.09

1-Week Range:

$13.42

$14.26

52-Week Range:

$1.94

$15.10

Immix Biopharma Inc Stock (IMMX) Company Profile

Name

Immix Biopharma Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(888) 958-1084

Address

11400 WEST OLYMPIC BLVD., LOS ANGELES

Employee

Twitter

Next Earnings Date

2026-08-14

Latest SEC Filings

IMMX's Discussions on Twitter

Compare IMMX vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMMX Immix Biopharma Inc	13.91	936.86M	0	-34.98M	-32.77M	-0.9199
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-25-26	Initiated	Morgan Stanley	Overweight
Mar-09-26	Initiated	Citizens	Mkt Outperform
Feb-09-26	Initiated	Mizuho	Outperform

Immix Biopharma Inc Stock (IMMX) Latest News

Aug 21, 2026

Tocqueville Asset Management L.P. Buys New Position in Immix Biopharma, Inc. $IMMX - MarketBeat

Aug 21, 2026

Blue Owl Capital Holdings LP Makes New $4.51 Million Investment in Immix Biopharma, Inc. $IMMX - MarketBeat

Aug 21, 2026

Aug 19, 2026

Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management - Stock Titan

Aug 14, 2026

Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com Australia

Aug 14, 2026

Citizens reiterates Immix Biopharma stock rating on pipeline progress - Investing.com

Aug 14, 2026

Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating - Moomoo

Aug 14, 2026

Aug 13, 2026

Janus Henderson Group (IMMX) discloses 9.78M-share beneficial stake in Immix Biopharma - Stock Titan

Aug 13, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc.IMMX - PR Newswire

Aug 13, 2026

Aug 12, 2026

Immix Biopharma Q3 EPS Estimate Lowered by HC Wainwright - MarketBeat

Aug 12, 2026

Aug 11, 2026

Immix Biopharma (NASDAQ:IMMX) Trading 7.1% HigherStill a Buy? - MarketBeat

Aug 11, 2026

HC Wainwright Estimates Immix Biopharma FY2027 Earnings - MarketBeat

Aug 11, 2026

Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis - Bitget

Aug 11, 2026

Immix Biopharma, Inc. Stock 12‑Month Price Target Cut to $20.44, Implies 102% Upside - TradingView

Aug 11, 2026

Aug 10, 2026

IMMIX BIOPHARMA, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $25 FROM $20 - Bitget

Aug 10, 2026

H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com - Investing.com Australia

Aug 10, 2026

H.C. Wainwright raises Immix Biopharma price target to $25 - Investing.com India

Aug 10, 2026

Regulatory and Data Risks Loom Over Immix Biopharma’s Clinical Programs and Valuation - TipRanks

Aug 10, 2026

Aug 07, 2026

Immix Biopharma (NASDAQ:IMMX) Announces Quarterly Earnings Results - MarketBeat

Aug 07, 2026

Immix Biopharma (NASDAQ: IMMX) ends Q2 2026 with $232.1M in cash - Stock Titan

Aug 07, 2026

Immix Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 07, 2026

Immix Biopharma (NASDAQ:IMMX) Stock Price Down 6.7%Here's What Happened - MarketBeat

Aug 07, 2026